There are several types of exciting drugs in the pipeline for Alzheimer's disease:
Beta-secretase 1 (BACE1) inhibitors. Beta-secretase is a protease or a molecular scissor that cuts the amyloid precursor protein ultimately giving rise to and producing beta-amyloid, the toxic component of amyloid plaques. Using an analogy from Dr. Bateman, if you have an overflowing sink, this type of drug aims to turn of the faucet off. Studies have shown that this treatment is very effective at suppressing the initiation of amyloid pathology. Thus, it will be important to administer this treatment in the early stages of plaque deposition.
Monoclonal antibodies against beta-amyloid. Many monoclonal antibodies have been developed that target various forms of beta-amyloid. The most promising of these include: gantenerumab, solanezumab, BAN2401, and aducanumab.
Gene therapy/editing technology (anti-sense oligonucleotides (ASOs) and CRISPR). Click here to learn more.
There are also other molecules that target different aspects/pathologies of the disease (tau, neuronal loss, inflammation, etc.).